Great Point Partners’s Lisata Therapeutics LSTA Stock Holding History

Great Point Partners’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,168	Closed	-$900K	–	43
2016 Q2	$900K	Sell	10,168 -1,236	-11%	-$114K	0.26%	30
2016 Q1	$1.28M	Sell	11,404 -3,588	-24%	-$353K	0.46%	28
2015 Q4	$2.43M	Hold	14,992	–	–	1.02%	20
2015 Q3	$3.35M	Sell	14,992 -1,515	-9%	-$380K	1.33%	24
2015 Q2	$4.63M	Buy	+16,507	New	+$6.13M	1.8%	20

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Great Point Partners's LSTA Position: Q3 2016 in Review

Great Point Partners sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 10,168 shares — an estimated $900K sold.

Great Point Partners first reported a position in LSTA in Q2 2015 and held it in 5 quarters. The position peaked at $4.63M in Q2 2015. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

Great Point Partners reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
Great Point Partners sold 10,168 Lisata Therapeutics shares in Q3 2016, an estimated $900K.
Great Point Partners first reported a position in Lisata Therapeutics in Q2 2015 and held it in 5 quarters.
Great Point Partners's Lisata Therapeutics position peaked at $4.63M in Q2 2015.
28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on Great Point Partners's 13F filing for Q3 2016, filed 14 Nov 2016.